Some blood pressure medications are not the best choice anymore, either due to their side effects or limited effectiveness.

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.